1609565-31-2

Upstream product

• 349-88-2 4-Fluorobenzenesulfonyl chloride 
• 588729-99-1 3-amino-5-bromo-2-chloropyridine 
• 887309-87-7 N-(5-bromo-2-chloro-pyridine-3-yl)-4-fluorobenzenesulfonamide 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1609565-30-1 N-(2-chloro-5-(3-((trimethylsilyl)ethynyl)imidazo[1,2-b]pyridazin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide 

Relevant academic research and scientific papers

Morphline and quinoline compound, preparation method thereof, and use thereof

The invention discloses a morpholinoquinoline compound represented by a formula (I) which is shown in the description, wherein the R1 represents a C1-C6 alkyl group, an aryl group, an amino group, a C3-C10 cycloalkyl group, a heterocyclic radical, or a heteroaryl group; the R2 represents H, a halogen element, or -OR10; the R3 represents H, -NHR10, or -NHC(=O)R10; the R4 represents H, a C1-C6 alkyl group, -C(=O)R10, or -S(=O)2R10; the R5 and R6 individually represent H, a C1-C6 alkyl group, or a halogen element; the R7 and R8 individually represent H, a C1-C6 alkyl group, or a halogen element, or the R7 and R8 can be emerged as =O; the R9 represents H, a C1-C6 alkyl group, -OR10, or a halogen element; the R10 represents H, a C1-C6 alkyl group, a C3-C10 cycloalkyl group, an aryl group, or a heteroaryl group; the alkyl groups, alkoxyl groups, aryl groups, and heteroaryl groups mentioned above in R1 to R10 can be optionally replaced by one or more groups, and these groups can be alkyl group, alkenyl group, alkynyl group, halogen elements, alkoxyl group, aryl group, heteroaryl group, amino group, cyan group, nitro group, carboxyl group, ester group, carbamyl group, sulfonyl group, sulfamic group, or the like. The morpholinoquinoline compound can be used as a drug to treat diseases related with PI3K/mTOR.

As the PI3K/mTOR inhibitor compound, its preparation and use

The invention discloses a compound used as a PI3K/mTOR inhibitor, which is a compound with a general formula of (IA) or (IB), wherein R1 is selected from hydrogen, halogen, alkyl, alkyloxy, and amido, or forms a fused ring with R2; R2 is selected from hydrogen, amido, sulfamine, sulfonylurea, alkyl, and alkyloxy, or forms a fused ring with R1; R3 is selected from hydrogen, and C1-C6 alkyl; R4 is selected from hydrogen, amido, acylamino, or sulfamine; R5 is selected from hydrogen, halogen, alkyl or alkyloxy. The invention also discloses a preparation method of the compound used as a PI3K/mTOR inhibitor, and an application of the compound as a drug in treating PI3K/mTOR related diseases, especially PI3K/mTOR related cancers.